The increased PD-L1 expression induced by chemotherapy [6,7,39] and timing for introducing immunotherapy in the treatment of advanced urothelial carcinoma might explain the negative result, because JAVELIN bladder 100 trial found that avelumab maintenance treatment possessed huge survival benefits for patients responding to chemotherapy [40]. Here, CD274 is linked to urothelial carcinoma.